CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Current assets:
cash and cash equivalents		$ 191,328	$ 194,385
Accounts receivable		172	323
Accounts receivable - related parties		768	5,524
Research and Development Incentives Receivable		2,501	4,541
Prepaid expenses and other current assets		5,896	8,268
Total current assets		200,665	213,041
Goodwill		12,209	12,209
Property and equipment, net		12,712	7,957
Intangible assets, net		27,479	28,269
Right of use assets, net		7,723	7,753
Other assets		1,028	976
Total assets		261,816	270,205
Current liabilities:
Accounts payable		4,327	3,748
Accrued expenses and other current liabilities		7,012	8,061
Operating lease liability, current		649	433
Total current liabilities		11,988	12,242
Non-Current liabilities:
Operating lease liability, non-current		10,005	8,340
Contingent consideration		1,710	1,711
Deferred tax liability, net		3,230	3,746
Other non-current liabilities		1,314	965
Total liabilities		28,247	27,004
Commitments and contingencies
Shareholders' equity:
Ordinary shares, £0.000025 nominal value; 38,357,025 shares authorized, issued and outstanding (December 31, 2022: authorized, issued and outstanding: 37,683,531)		1	1
Additional paid-in capital		383,523	379,504
Accumulated deficit		(121,423)	(103,243)
Accumulated other comprehensive loss - foreign currency translation adjustments		(28,886)	(33,460)
Total shareholders' equity attributable to Vaccitech plc shareholders'		233,301	242,896
Noncontrolling interest		268	305
Total shareholders' equity		233,569	243,201
Total liabilities and shareholders' equity		261,816	270,205
Deferred A shares
Shareholders' equity:
Deferred shares		$ 86	86
Deferred B shares
Shareholders' equity:
Deferred shares			8
Deferred C shares
Shareholders' equity:
Deferred shares	[1]		$ 0

[1] indicates amount less than thousand